All Pharmaceutical industry articles
View all stories with this category.
-
BusinessUK grants Pfizer–BioNTech Covid-19 vaccine emergency approval
Regulators around the world working towards accelerated decisions on vaccine data
-
Business
Brexit may put some chemicals out of GB’s Reach
Industry fears divergence of UK and EU regulations could spell disaster for trade
-
-
Business
Oxford–AstraZeneca vaccine joins others with promising interim data
Cheap and fridge-stable candidate at least 60% and up to 90% effective at preventing disease
-
Business
Regulatory panel unconvinced by Alzheimer’s antibody evidence
US FDA advisors vote against approving Biogen’s aducanumab on the basis of incomplete data analysis
-
Business
Moderna and Pfizer’s Covid-19 vaccines add more encouraging data
Pfizer–BioNTech reach safety threshold for emergency authorisation, while Moderna’s data peek suggests 95% efficacy
-
Sponsored
The future is bright: protecting innovation during uncertain times
The annual Pharma Integrates event facilitates conversation and collaboration to drive future innovation and improve patient outcomes worldwide
-
Opinion
The ins and outs of vaccine trials
Derek Lowe lays out how the trials work, and why they get paused and restarted
-
Opinion
A promising peep at Covid-19 vaccine efficacy
Pfizer–BioNTech’s will need to be one of many if we are to overcome the pandemic
-
Business
Early indications suggest Pfizer–BioNTech’s Covid-19 vaccine is effective
Company claims 90% efficacy at preventing disease, but experts call for data rather than press releases
-
Business
Innovation is a fragile transition state
Brexit and Covid-19 will likely stifle interactions, but could also stimulate new ones
-
Business
Stepping towards diversity in industry
Companies are re-affirming their commitment to inclusivity, even as the US government obstructs education efforts
-
Opinion
Improving executive diversity is a priority
A few hiring decisions could make a big difference at leadership level
-
Podcast
Sofosbuvir
The hepatitis C drug that made waves when first launched – quicker to work and with fewer side effects than existing drugs, but it came with a hefty price tag
-
Business
EU commits to overhaul of chemicals legislation
The Chemicals Strategy for Sustainability promises the biggest reform since Reach
-
Business
Covid-19 highlights need to update pharma supply chains
Resilience and redundancy are key amid protectionist calls for domestic manufacturing
-
Opinion
Blood offering
Antibodies in various forms could bridge the Covid-19 treatment gap until a vaccine is available
-
Opinion
Jumping the vaccine queue
Deals between companies and rich governments offset manufacturing risks, but must not compromise supplies to those in need
-
Business
Covid-19 vaccine deals risk skewing supply
International accords including Covax aiming to ensure equitable distribution to poorer countries
-
Business
Protein-based Covid-19 vaccines could overshadow rivals
Although slower to develop, protein-based vaccines are well understood with a strong record of safety and effectiveness
